ReleaseWire

MedVax Technologies, Inc. , a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive Officer, will be presenting a company overview at the 6th Annual Biotech Showcase investor and partnering conference on Wednesday, January 15, 2014 at 1:45 p.m. Pacific (10:45 a.m. Eastern) at the Parc 55 Wyndham - Union Square, San Francisco, CA.

GlobalData's clinical trial report, "Xerosis (Dry Skin) Global Clinical Trials Review, H1, 2014" provides data on the Xerosis (Dry Skin) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Xerosis (Dry Skin). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Xerosis (Dry Skin). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

After being recommended by weight loss experts, and having been found to be effective at promoting weight loss in clinical studies, garcinia cambogia has quickly become very popular with dieters.

OTC Medications in Indonesia by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2013. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Indonesia is given in IDR with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Indonesia. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

Global Markets Direct's, 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

GlobalData's clinical trial report, "Strabismus Global Clinical Trials Review, H1, 2014" provides data on the Strabismus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Strabismus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Strabismus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Global Markets Direct's, 'Rhabdomyosarcoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players

Global Markets Direct's, 'Retinal Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinal Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinal Degeneration. Retinal Degeneration - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

GlobalData's clinical trial report, "Reperfusion Injury Global Clinical Trials Review, H1, 2014" provides data on the Reperfusion Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Reperfusion Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Reperfusion Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Market Direct's pharmaceuticals report, "TWi Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the TWi Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Global Markets Direct's, 'Francisella Tularensis Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Francisella Tularensis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections. Francisella Tularensis Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Endometriosis is a gynecological disorder affecting women of childbearing age. This inflammatory condition is characterized by the growth of endometrial tissues outside of the uterus, and can cause chronic painful menstruation, painful intercourse, and infertility. For many women, endometriosis-associated pain can be so debilitating that it affects their ability to perform daily functions and significantly deters their quality of life.

Natural weight loss should be aimed for as much as possible, although it can prove to be a challenge to many people. With the help of raspberry ketone weight loss supplement , however, reducing overall body fat and consequently losing weight through natural means has become more achievable.

GlobalData's clinical trial report, "Orthostatic Hypotension Global Clinical Trials Review, H1, 2014" provides data on the Orthostatic Hypotension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Orthostatic Hypotension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Orthostatic Hypotension. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Market Direct's pharmaceuticals report, "Aegis Therapeutics, LLC - Product Pipeline Review - 2013" provides data on the Aegis Therapeutics, LLC's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Global Market Direct's pharmaceuticals report, "Jenrin Discovery, Inc. - Product Pipeline Review - 2013" provides data on the Jenrin Discovery, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

GlobalData's clinical trial report, "Ulcers Global Clinical Trials Review, H1, 2014" provides data on the Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ulcers. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

OTC Medications in Japan by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2013. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Japan is given in JPY with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Japan. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

Atrasentan (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022